Amgen announced that the International Trade Commission in Washington, D.C. has agreed to look into a claim that the Thousand Oaks biotech company lodged against Switzerland-based Roche. Amgen claims that Roche’s importation of pegylated recombinant human erythropoietin violates six of Amgen’s patents and does not provide any benefit over Amgen’s existing treatments. Amgen, which is also suing Roche in federal court, is asking the ITC to prohibit importation of peg-EPO into the United States and expects the full investigation to take several months.